Abivax (AAVXF) EBITDA (2022 - 2026)

Abivax has reported EBITDA for 5 years, with the latest figure at -$65.8 million in Q1 2026.

• On a quarterly basis, EBITDA fell 32.59% year-over-year to -$65.8 million in Q1 2026; TTM through Mar 2026 was -$296.2 million, a 9.57% increase from a year earlier, with the FY2025 full-year figure at -$286.4 million, down 54.95% from the prior year.
• EBITDA was -$65.8 million for Q1 2026 at Abivax, up from -$83.4 million in the prior quarter.
• The five-year high for EBITDA was -$38.0 million in Q2 2024, with the low at -$184.8 million in Q4 2024.
• Average EBITDA over 5 years is -$79.6 million, with a median of -$65.8 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2025: EBITDA sank 107.34% in 2023, then surged 54.86% in 2025.
• Over 5 years, EBITDA stood at -$66.1 million in 2022, then plunged by 107.34% to -$137.1 million in 2023, then plunged by 34.79% to -$184.8 million in 2024, then soared by 54.86% to -$83.4 million in 2025, then increased by 21.07% to -$65.8 million in 2026.
• The last three EBITDA figures came in at -$65.8 million (Q1 2026), -$83.4 million (Q4 2025), and -$94.4 million (Q3 2025), per Business Quant data.